Genomic diagnostics company. Could be part of the genomic revolution.
Not so cheap anymore, high risk high reward
Not so cheap anymore, high risk high reward
Note
earnings tomorrow after close,looking to buy breakout 8.50 or support channel trendline
Note
add more on breakoutNote
Long sideways period but still holding and accumulated more of this stock. Adjusted channel.Some news: "Veracyte Chairman and CEO Bonnie Anderson Receives Prestigious Innovation Award at Biomedical Engineering Society Annual Meeting- The Coulter Foundation’s Wallace H. Coulter Award for Healthcare Innovation Recognizes Excellence and Leadership in Clinical Diagnostic Medicine"
businesswire.com/news/home/20171013005391/en/
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.